Seven Potential Blockbuster Approvals To Look Out For In 2023
After highlighting oncology drugs pegged to make a splash next year with the help of Biomedtracker, Scrip takes a look at seven potential blockbusters across a range of therapeutic areas including neurology, dermatology and blood disorders slated for approval next year.
![Piggy Money](https://insights.citeline.com/resizer/v2/23JAOVES5ZOKDBRCDUQI22UQPE.jpg?smart=true&auth=66c86901c93f7bdc92a0fedfd3ff0e094f6dd2e607b63c802c923099c871d6ae&width=700&height=394)